Atriva Therapeutics GmbH

Quick facts

Phase 1 pipeline

• ATR-002 MEK Inhibitor · Oncology
  MEK inhibitor

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Atriva Therapeutics GmbH portfolio CI brief
• Atriva Therapeutics GmbH pipeline updates RSS